Norway Savings Bank Lowers Stake in Pfizer Inc. $PFE

Norway Savings Bank reduced its stake in shares of Pfizer Inc. (NYSE:PFE) by 6.6% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 13,506 shares of the biopharmaceutical company’s stock after selling 958 shares during the quarter. Norway Savings Bank’s holdings in Pfizer were worth $327,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in PFE. Gould Capital LLC boosted its stake in shares of Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 493 shares during the period. GKV Capital Management Co. Inc. bought a new stake in shares of Pfizer in the first quarter valued at about $27,000. North Capital Inc. bought a new stake in shares of Pfizer in the first quarter valued at about $28,000. Bayforest Capital Ltd bought a new stake in shares of Pfizer in the first quarter valued at about $28,000. Finally, Bernard Wealth Management Corp. bought a new stake in shares of Pfizer in the fourth quarter valued at about $30,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Stock Performance

Shares of Pfizer stock opened at $23.91 on Friday. The company has a market capitalization of $135.94 billion, a PE ratio of 12.72, a P/E/G ratio of 0.88 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The company has a 50-day simple moving average of $24.79 and a two-hundred day simple moving average of $24.30. Pfizer Inc. has a one year low of $20.92 and a one year high of $30.43.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. The business had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm’s revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the company posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th were issued a dividend of $0.43 per share. The ex-dividend date was Friday, July 25th. This represents a $1.72 annualized dividend and a dividend yield of 7.2%. Pfizer’s dividend payout ratio is 91.49%.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on PFE. Jefferies Financial Group lifted their price objective on Pfizer from $32.00 to $33.00 and gave the company a “buy” rating in a report on Wednesday, May 21st. Bank of America lifted their price objective on Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Citigroup lifted their price objective on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Morgan Stanley lifted their price objective on Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a report on Wednesday, August 6th. Finally, HSBC decreased their price objective on Pfizer from $27.00 to $26.00 and set a “buy” rating for the company in a report on Monday, May 19th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Pfizer has a consensus rating of “Hold” and an average price target of $28.12.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.